About Versartis
Versartis is a publicly listed company based in Redwood City (United States) founded in 2008. Biopharma company developing long-acting therapeutic proteins for the treatment of endocrine disorders. Versartis has raised $144.5 million across 6 funding rounds from investors including New Leaf Venture Partners, Sofinnova and Aisling Capital. The company has 5 employees. Its chief executive, as recorded, is Jay Shepard. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its legal entity is VERSARTIS, INC. Its competitors include Neurocrine, Crinetics and MBX Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Versartis is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. It utilises proprietary XTEN technology which extends the half-life of therapeutic protein thereby makes it long-acting. Pipeline includes velocity program having long-acting growth hormone for children undergoing clinical trial phase 3 in USA, Canada and Europe; J14VR5 program having somavaratan for pre-puberty children having growth hormone deficiency in clinical trial phase 2 in Japan; and Vital program having somavaratan undergoing clinical trial phase 2 in USA, Australis, Germany and UK
- Headquarters Redwood City, United States
- Employees 5
- Stage Public
- SectorsHealthcare
- Website versartis.com
- Social LinkedIn
- Legal Name Versartis, Inc.
- Total Equity Funding$144.5M (USD)
in 6 rounds
- Latest Funding Round$55M (USD), Series E
Feb 2014
- InvestorsNew Leaf Venture Partners
& 4 more
- Employee Count5
Funding Insights of Versartis
Versartis has successfully raised a total of $144.5M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $55 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $144.5M
- Total Rounds 6
- Last Round Series E — $55M
- First Round $11M
(Jun 2009)
- Investors Count 5
All 6 funding rounds of Versartis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2014 | $55M | Series E | – | – | |
| Oct 2013 | $20M | Series D | – | Sofinnova Investments | |
| Jul 2013 | $12.5M | Series C | – | – | |
| Jan 2013 | $25M | Series C | – | Aisling Capital | |
| Feb 2011 | $21M | Series B | – | – | |
| Jun 2009 | $11M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Versartis
Versartis has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include New Leaf Venture Partners, Sofinnova and Aisling Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Venture capital investments in technology startups and entrepreneurs. | indexventures.com | |||
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom |
Investor details for Versartis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Versartis
1 people are tracked at Versartis (1 in leadership); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
Jay Shepard | CEO | Leadership |
Complete people profiles for Versartis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Versartis
4 dated milestones of Versartis across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Versartis is founded.
- Funding First funding round of $11.0M.
- Funding Latest funding round, Series E, of $55.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Versartis
Versartis has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, Crinetics and MBX Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| mbxbio.com | 2018 | Carmel, United States | $215.6M | 11 | Drugs for rare endocrine diseases are developed and advanced. |
Detailed competitors of Versartis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Versartis
Websites that share an audience with Versartis (versartis.com).
Websites whose visitors overlap most with Versartis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| indexventures.com | 100% | #302,583 | View details | ||
| q2ebanking.com | 60% | 134.6K | #227,735 | View details | |
remoteoffice.citigroup.com | remoteoffice.citigroup.com | 60% | – |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Versartis (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Versartis
Complete news archive for Versartis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Versartis
Versartis was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Versartis is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Jay Shepard is the CEO of Versartis, as recorded in our data.
Versartis is a funded company, having raised a total of $144.5M across 6 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Jun 2009.
Versartis has 5 employees.
Versartis is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. It utilises proprietary XTEN technology which extends the half-life of therapeutic protein thereby makes it long-acting. Pipeline includes velocity program having long-acting growth hormone for children undergoing clinical trial phase 3 in USA, Canada and Europe; J14VR5 program having somavaratan for pre-puberty children having growth hormone deficiency in clinical trial phase 2 in Japan; and Vital program having somavaratan undergoing clinical trial phase 2 in USA, Australis, Germany and UK.
Versartis's top competitors include Crinetics, Neurocrine and MBX Biosciences.
Versartis has 5 investors. Key investors include New Leaf Venture Partners, Sofinnova, Aisling Capital, Index Ventures, and Advent Life Sciences.
Versartis operates through Versartis, Inc..